$CKPT
Checkpoint Therapeutics, Inc. Stock $ckpt

$ckpt Overview Financials Valuation SEC Filings Company Website

2017 Form 10-K Financial Statement

#000114420418015101 Filed on March 16, 2018

Income Statement

Concept	2017	2016 Q4	2016 Q3
Revenue	$1.730M	$500.0K	$550.0K
YoY Change	-32.68%	614.29%	1733.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.420M	$1.090M	$970.0K
YoY Change	21.25%	-49.54%	340.91%
% of Gross Profit
Research & Development	$19.08M	$7.740M	$4.713M
YoY Change	-5.85%	44.4%	35.24%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$24.50M	$8.833M	$5.685M
YoY Change	-0.95%	17.54%	53.48%
Operating Profit	-$22.78M		-$5.139M
YoY Change	2.76%		39.68%
Interest Expense	$0.00	$10.00K	$0.00
YoY Change	-100.0%	-106.25%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$98.00K	$12.00K	$11.00K
YoY Change	-133.0%	-102.0%	-115.71%
Pretax Income	-$22.68M	-$8.320M	-$5.130M
YoY Change	0.98%	3.35%	36.8%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$22.68M	-$8.323M	-$5.128M
YoY Change	0.96%	3.38%	36.78%
Net Earnings / Revenue	-1310.81%	-1664.6%	-932.36%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.003M	-$380.4K	-$235.3K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2017	2016 Q4	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.23M	$35.09M	$39.35M
YoY Change	-45.2%
Cash & Equivalents	$19.23M	$35.09M	$39.35M
Short-Term Investments
Other Short-Term Assets	$1.860M	$821.0K	$574.0K
YoY Change	2557.14%	1163.08%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$21.41M	$35.98M	$39.95M
YoY Change	-40.49%	-28.97%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$21.41M	$35.98M	$39.95M
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$21.41M	$35.98M	$39.95M
YoY Change	-40.49%	-28.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.650M	$2.473M	$4.460M
YoY Change	47.77%	169.68%
Accrued Expenses	$410.0K	$290.0K
YoY Change	41.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.370M	$3.673M	$4.459M
YoY Change	73.57%	105.2%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.370M	$3.673M	$4.459M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$6.370M	$3.673M	$4.459M
YoY Change	73.57%	-13.74%
SHAREHOLDERS EQUITY
Retained Earnings		-$36.35M	-$28.03M
YoY Change		161.68%
Common Stock		$2.000K	$2.000K
YoY Change		100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.04M	$32.31M	$35.49M
YoY Change
Total Liabilities & Shareholders Equity	$21.41M	$35.98M	$39.95M
YoY Change	-40.49%	-28.97%

Cashflow Statement

Concept	2017	2016 Q4	2016 Q3
OPERATING ACTIVITIES
Net Income	-$22.68M	-$8.323M	-$5.128M
YoY Change	0.96%	3.38%	36.78%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$15.46M	-$4.170M	-$1.890M
YoY Change	55.39%	471.23%	-20.92%
INVESTING ACTIVITIES
Capital Expenditures	-$400.0K	-$100.0K	-$1.000M
YoY Change	-87.34%	-81.13%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$400.0K	-$100.0K	-$1.000M
YoY Change	-87.34%	-81.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change	-100.0%	-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-15.46M	-4.170M	-1.890M
Cash From Investing Activities	-400.0K	-100.0K	-1.000M
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	-15.86M	-4.270M	-2.890M
YoY Change	3.45%	-110.9%	-125.73%
FREE CASH FLOW
Cash From Operating Activities	-$15.46M	-$4.170M	-$1.890M
Capital Expenditures	-$400.0K	-$100.0K	-$1.000M
Free Cash Flow	-$15.06M	-$4.070M	-$890.0K
YoY Change	121.81%	1935.0%	-62.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q2	dei	Entity Public Float EntityPublicFloat	123985657	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19225000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35086000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1857000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	71000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	331000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	821000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	21413000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	35978000	USD
CY2017Q4	us-gaap	Assets Assets	21413000	USD
CY2016Q4	us-gaap	Assets Assets	35978000	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5762000	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3355000	USD
CY2017Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	610000	USD
CY2016Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	318000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6372000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3673000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	6372000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	3673000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	71772000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	64736000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59030000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36353000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	15041000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	32305000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21413000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35978000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2017Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	2296000	USD
CY2016Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	3919000	USD
CY2017	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	1725000	USD
CY2016	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	2570000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19081000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20267000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5419000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4467000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	24500000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	24734000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-22775000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-22164000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	98000	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	47000	USD
CY2017	us-gaap	Interest Expense InterestExpense	0	USD
CY2016	us-gaap	Interest Expense InterestExpense	344000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	98000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-297000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-22677000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-22461000	USD
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.04
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22618931	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21544205	shares
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2015	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	590000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11323000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2488000	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	13811000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-13221000	USD
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	438000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-13892000	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.41
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9855668	shares
CY2016	ck0001651407	Stock Issued During Period Value Common Shares And Warrants New Issues StockIssuedDuringPeriodValueCommonSharesAndWarrantsNewIssues	570000	USD
CY2016	ck0001651407	Stock Issued During Period Value Common Shares For Services StockIssuedDuringPeriodValueCommonSharesForServices	14000	USD
CY2015	ck0001651407	Stock Issued During Period Value Common Shares For Services StockIssuedDuringPeriodValueCommonSharesForServices	1269000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	1000	USD
CY2015	ck0001651407	Stocks Issued During Period Value Issued For Cash StocksIssuedDuringPeriodValueIssuedForCash	57817000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	6321000	USD
CY2015	ck0001651407	Stock Issued During Period Value Issuable For Services StockIssuedDuringPeriodValueIssuableForServices	3024000	USD
CY2015	ck0001651407	Stock Issued During Period Value Restricted Stock And Warrants For Services StockIssuedDuringPeriodValueRestrictedStockAndWarrantsForServices	2987000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	613000	USD
CY2015	ck0001651407	Stock Issued During Period Value Issued For Other Services StockIssuedDuringPeriodValueIssuedForOtherServices	633000	USD
CY2016	ck0001651407	Stock Issued During Period Value Issuable For Services StockIssuedDuringPeriodValueIssuableForServices	3919000	USD
CY2015	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	265000	USD
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	3867000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	3867000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	3252000	USD
CY2016	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	14000	USD
CY2015	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1269000	USD
CY2016	ck0001651407	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	0	USD
CY2015	ck0001651407	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	633000	USD
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	324000	USD
CY2015	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	89000	USD
CY2016	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	3160000	USD
CY2015	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	2525000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-100000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	171000	USD
CY2016	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	756000	USD
CY2015	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	65000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1883000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1790000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9950000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1108000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3160000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2525000	USD
CY2016	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2015	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2554000	USD
CY2016	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2792000	USD
CY2015	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2016	ck0001651407	Proceeds From Issuance Of Common Stock Net Of Offering Costs ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts	570000	USD
CY2015	ck0001651407	Proceeds From Issuance Of Common Stock Net Of Offering Costs ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts	51496000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2222000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54051000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-15332000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	50418000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50418000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	20000	USD
CY2015	us-gaap	Interest Paid Net InterestPaidNet	56000	USD
CY2016	ck0001651407	Common Shares Issuable Under Founder Agreement CommonSharesIssuableUnderFounderAgreement	3919000	USD
CY2015	ck0001651407	Common Shares Issuable Under Founder Agreement CommonSharesIssuableUnderFounderAgreement	3024000	USD
CY2016	ck0001651407	Debt Discount Associated With Warrant Liabilities DebtDiscountAssociatedWithWarrantLiabilities	0	USD
CY2015	ck0001651407	Debt Discount Associated With Warrant Liabilities DebtDiscountAssociatedWithWarrantLiabilities	175000	USD
CY2016	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	0	USD
CY2015	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	1000	USD
CY2016	ck0001651407	Payment For Research And Development Licenses PaymentForResearchAndDevelopmentLicenses	3160000	USD
CY2015	ck0001651407	Payment For Research And Development Licenses PaymentForResearchAndDevelopmentLicenses	2525000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	3117000	USD
CY2017	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2017	ck0001651407	Common Shares Issuable Under Founder Agreement CommonSharesIssuableUnderFounderAgreement	2296000	USD
CY2017	ck0001651407	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	0	USD
CY2017	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1786000	USD
CY2017	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-490000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2699000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15461000	USD
CY2017	ck0001651407	Payment For Research And Development Licenses PaymentForResearchAndDevelopmentLicenses	400000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-400000	USD
CY2017	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2017	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2017	ck0001651407	Proceeds From Issuance Of Common Stock Net Of Offering Costs ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts	0	USD
CY2017	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	0	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-15861000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2017	ck0001651407	Debt Discount Associated With Warrant Liabilities DebtDiscountAssociatedWithWarrantLiabilities	0	USD
CY2016	us-gaap	Stock Issued1 StockIssued1	3024000	USD
CY2015	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2017	us-gaap	Stock Issued1 StockIssued1	3919000	USD
CY2015Q1	ck0001651407	Equity Method Investment Annual Equity Feepercentage EquityMethodInvestmentAnnualEquityFeepercentage	0.025	pure
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	2900000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	60000	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	60000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.43
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.43
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M2D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y11M16D
CY2016	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3867000	USD
CY2017	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3117000	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.11	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.01	pure
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10662000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5148000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1839000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1624000	USD
CY2017Q4	ck0001651407	Deferred Tax Assets Tax Deferred Expense Change In Fair Value Of Warrant Liabilities DeferredTaxAssetsTaxDeferredExpenseChangeInFairValueOfWarrantLiabilities	149000	USD
CY2016Q4	ck0001651407	Deferred Tax Assets Tax Deferred Expense Change In Fair Value Of Warrant Liabilities DeferredTaxAssetsTaxDeferredExpenseChangeInFairValueOfWarrantLiabilities	157000	USD
CY2017Q4	ck0001651407	Deferred Tax Assets Amortization Of License DeferredTaxAssetsAmortizationOfLicense	5410000	USD
CY2016Q4	ck0001651407	Deferred Tax Assets Amortization Of License DeferredTaxAssetsAmortizationOfLicense	4656000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	11000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	25000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	905000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	733000	USD
CY2017Q4	ck0001651407	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	46000	USD
CY2016Q4	ck0001651407	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	54000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	19022000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	12397000	USD
CY2016Q4	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	498000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19022000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12397000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3645000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2473000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	405000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	291000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1466000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	378000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	246000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	213000	USD
CY2017Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	693000	USD
CY2017Q2	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	351000	USD
CY2017Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	349000	USD
CY2017Q4	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	332000	USD
CY2016Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	277000	USD
CY2016Q2	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	1249000	USD
CY2016Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	546000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	5107000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	6823000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	6299000	USD
CY2017Q4	us-gaap	Operating Expenses OperatingExpenses	6271000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	3549000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	6667000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	5685000	USD
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	8833000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-333000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	13000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11000	USD
CY2016Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-4383000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-6448000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-5928000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-5918000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-3605000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-5405000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-5128000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-8323000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.2
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18512429	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18512429	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17426876	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17426876	shares
CY2017Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	591836	shares
CY2016Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	721699	shares
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	3117000	USD
CY2017	ck0001651407	Stock Issued During Period Value Common Shares For Services StockIssuedDuringPeriodValueCommonSharesForServices	0	USD
CY2017	ck0001651407	Stock Issued During Period Value Issuable For Services StockIssuedDuringPeriodValueIssuableForServices	2296000	USD
CY2017	ck0001651407	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	0	USD
CY2017	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	400000	USD
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	6321000	USD
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016	ck0001651407	Effective Income Tax Rate Reconciliation Provision To Return EffectiveIncomeTaxRateReconciliationProvisionToReturn	0.05	pure
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6924169	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6997671	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6786782	shares
CY2017Q1	ck0001651407	Agreement Description Terms AgreementDescriptionTerms	(i) issue annually to Fortress, on the anniversary date of the Founders Agreement, shares of common stock equal to two and one-half percent (2.5%) of the fully-diluted outstanding equity of Checkpoint at the time of issuance; (ii) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Checkpoint or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when Fortress no longer has majority voting control in Checkpoint’s voting equity, equal to two and one-half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of Checkpoint’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), Checkpoint will pay a one-time change in control fee equal to five times (5x) the product of (i) monthly net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).
CY2015	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3252000	USD
CY2017Q4	ck0001651407	Shelf Registration Statement Maximum Authorized Securities ShelfRegistrationStatementMaximumAuthorizedSecurities	100000000	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.02	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.03	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.27	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0	pure
CY2017	ck0001651407	Effective Income Tax Rate Reconciliation Change In State Tax Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateTaxRatePercent	0.08	pure
CY2016	ck0001651407	Effective Income Tax Rate Reconciliation Change In State Tax Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateTaxRatePercent	-0.02	pure
CY2017	ck0001651407	Effective Income Tax Rate Reconciliation Provision To Return EffectiveIncomeTaxRateReconciliationProvisionToReturn	0.05	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.04	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.04	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.02	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.36	pure
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2017Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	31000	USD
CY2017Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	24000	USD
CY2017Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	22000	USD
CY2017Q4	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	21000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	0	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	46396000	USD
CY2015Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	324000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6200000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	0	USD

Files In Submission

Name	View Source	Status
0001144204-18-015101-index-headers.html	Edgar Link	pending
0001144204-18-015101-index.html	Edgar Link	pending
0001144204-18-015101.txt	Edgar Link	pending
0001144204-18-015101-xbrl.zip	Edgar Link	pending
ck0001651407-20171231.xml	Edgar Link	completed
ck0001651407-20171231.xsd	Edgar Link	pending
ck0001651407-20171231_cal.xml	Edgar Link	unprocessable
ck0001651407-20171231_def.xml	Edgar Link	unprocessable
ck0001651407-20171231_lab.xml	Edgar Link	unprocessable
ck0001651407-20171231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv487632ex10-16_1.htm	Edgar Link	pending
tv487632ex10-21_1.htm	Edgar Link	pending
tv487632_10k.htm	Edgar Link	pending
tv487632_ex23-1.htm	Edgar Link	pending
tv487632_ex23-2.htm	Edgar Link	pending
tv487632_ex31-1.htm	Edgar Link	pending
tv487632_ex31-2.htm	Edgar Link	pending
tv487632_ex32-1.htm	Edgar Link	pending
tv487632_ex32-2.htm	Edgar Link	pending
tv487632_img1.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CKPT
Checkpoint Therapeutics, Inc. Stock $ckpt

2017 Form 10-K Financial Statement

#000114420418015101 Filed on March 16, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CKPT Checkpoint Therapeutics, Inc. Stock $ckpt

2017 Form 10-K Financial Statement

#000114420418015101 Filed on March 16, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CKPT
Checkpoint Therapeutics, Inc. Stock $ckpt